Empowered Patient Podcast

Joseph Pandolfino, Founder and CEO of Cabbacis, is focused on reducing harm caused by smoking cigarettes by developing cigarettes made from a blend of low-nicotine tobacco and hemp. This approach is intended to help smokers reduce their nicotine dependence and increase the success rate of those who are looking to quit smoking. Their products are targeted to established smokers by providing the taste and sensory experience of a traditional cigarette while providing significantly less nicotine and a path to less harmful non-combustible products.

Joseph explains, "So our products in development are called iBlend. We'll stick with the cigarette right now. So iBlend is predominantly very low-nicotine tobacco, and you add hemp to the product. Hemp became legal at the federal level in 2018 for farmers. So every iBlend is the merger of very low-nicotine tobacco and hemp, which really creates the taste and sensory characteristics of a cigarette that just has very little nicotine tobacco."

"As I mentioned, currently nicotine is reduced by about 95%. They give you a little bit of nicotine but not enough to really sustain addiction. So the result is that people smoke less cigarettes and it has greatly increased their quit attempts. And while they reduce their nicotine exposure and dependence, if they choose to switch to a non-combustible, we consider that a win as far as we're concerned."

#Cabbacis $CABI #EmpoweredPatient #HarmReduction #TobaccoHarmReduction #SmokingCessation #QuitSmoking #iBlend #FDA #PublicHealth #TobaccoControl #PublicHealth #Healthcare

cabbacis.com

Listen to the podcast here

Joseph Pandolfino, Founder and CEO of Cabbacis, is focused on reducing harm caused by smoking cigarettes by developing cigarettes made from a blend of low-nicotine tobacco and hemp. This approach is intended to help smokers reduce their nicotine dependence and increase the success rate of those who are looking to quit smoking. Their products are targeted to established smokers by providing the taste and sensory experience of a traditional cigarette while providing significantly less nicotine and a path to less harmful non-combustible products.

Joseph explains, "So our products in development are called iBlend. We'll stick with the cigarette right now. So iBlend is predominantly very low-nicotine tobacco, and you add hemp to the product. Hemp became legal at the federal level in 2018 for farmers. So every iBlend is the merger of very low-nicotine tobacco and hemp, which really creates the taste and sensory characteristics of a cigarette that just has very little nicotine tobacco."

"As I mentioned, currently nicotine is reduced by about 95%. They give you a little bit of nicotine but not enough to really sustain addiction. So the result is that people smoke less cigarettes and it has greatly increased their quit attempts. And while they reduce their nicotine exposure and dependence, if they choose to switch to a non-combustible, we consider that a win as far as we're concerned."

#Cabbacis $CABI #EmpoweredPatient #HarmReduction #TobaccoHarmReduction #SmokingCessation #QuitSmoking #iBlend #FDA #PublicHealth #TobaccoControl #PublicHealth #Healthcare

cabbacis.com

Download the transcript here

Brian Robertson, Founder and CEO of VisiQuate, describes the relationship between payers and providers, noting that payers have the advantage due to unified data and lower complexity than providers face. He emphasizes that providers could level the playing field by unifying their data and leveraging AI to predict and prevent claim denials and solve systemic problems. The ultimate goal of using data and AI in the revenue cycle should be patient-centered, ensuring that the technology leads to more accurate billing and better outcomes for patients, providers, and payers.

Brian explains, "I would say in general, and I think a lot of us in the industry know this, the payer or the health plan has the edge, partly because they have fewer jobs to be done every day. They manage a financial risk engine for the most part. And if you consider that the other side of that is the provider who has to have all the upfront labor, all of the upfront dollars, they have to think about every permutation of care and patient satisfaction and physician satisfaction. So good care benefits for patients. So there are a thousand jobs to be done on the provider side, and I'll just say fewer jobs to be done on the health plan side. And the health plan side controls the money."

"I think in today's world of AI, he who has the more unified data has the edge. And I think there's little debate that the payer right now has the edge because they have a unified dataset and are a financial risk engine. So, I think the opportunity is for providers to use the power of data now to begin to bring a little bit more balance to that question. And they've got a hard job ahead of them, for sure."

"So our core value proposition is really centered on data unification. We're getting into many case accounts, transactions, charges, claim files, remittance files, and third-party data sets from providers who sometimes are on one system of record. Often, they're on many systems of record. So we have to get all of that fragmented data, normalize, cleanse, unify, and curate that data for action."

#VisiQuate #HealthcareFinance #RevenueCycleManagement #AIinHealthcare #DataUnification #DeniedClaims #HealthIT #PayerProvider #PatientExperience

VisiQuate.com

Listen to the podcast here

Brian Robertson, Founder and CEO of VisiQuate, describes the relationship between payers and providers, noting that payers have the advantage due to unified data and lower complexity than providers face. He emphasizes that providers could level the playing field by unifying their data and leveraging AI to predict and prevent claim denials and solve systemic problems. The ultimate goal of using data and AI in the revenue cycle should be patient-centered, ensuring that the technology leads to more accurate billing and better outcomes for patients, providers, and payers.

Brian explains, "I would say in general, and I think a lot of us in the industry know this, the payer or the health plan has the edge, partly because they have fewer jobs to be done every day. They manage a financial risk engine for the most part. And if you consider that the other side of that is the provider who has to have all the upfront labor, all of the upfront dollars, they have to think about every permutation of care and patient satisfaction and physician satisfaction. So good care benefits for patients. So there are a thousand jobs to be done on the provider side, and I'll just say fewer jobs to be done on the health plan side. And the health plan side controls the money."

"I think in today's world of AI, he who has the more unified data has the edge. And I think there's little debate that the payer right now has the edge because they have a unified dataset and are a financial risk engine. So, I think the opportunity is for providers to use the power of data now to begin to bring a little bit more balance to that question. And they've got a hard job ahead of them, for sure."

"So our core value proposition is really centered on data unification. We're getting into many case accounts, transactions, charges, claim files, remittance files, and third-party data sets from providers who sometimes are on one system of record. Often, they're on many systems of record. So we have to get all of that fragmented data, normalize, cleanse, unify, and curate that data for action."

#VisiQuate #HealthcareFinance #RevenueCycleManagement #AIinHealthcare #DataUnification #DeniedClaims #HealthIT #PayerProvider #PatientExperience

VisiQuate.com

Download the transcript here

Debra Berenson is Chair of the Fundraising Committee at the Institute for Myeloma & Bone Cancer Research and author of two books- I Have WHAT and You Have WHAT, based on her personal experience and the expertise of her husband, Dr. Jim Berenson, a myeloma expert. Multiple myeloma and related bone cancers are increasingly common, and her books are designed to help patients and caregivers understand the diagnosis and treatment options. Debra emphasizes that treatments have advanced significantly, leading to much longer, higher-quality lives for patients and transforming these diseases into chronic, manageable conditions.

Debra explains, "I thought, "If I had this disease, what would I do?" And I used to be a reporter, so that's how I told my husband I wanted to write these books - like interviews. I wanted to interview different patients with these diseases. I wanted to get the real stories out there of what it was really like having one of these diseases - the good, bad, and the ugly of dealing with all of them, and what helped these patients and what didn't help them."

"I also thought it would be cathartic for the patient who could share their journey, and also helpful for the new patient. That's the first part of the book - interviews with the different patients who have the four different diseases that Jim treats. The second part of the book is made up of the medical professionals who treat these diseases. I interviewed Jim about myeloma and its related diseases and asked him to weigh in with his medical opinions in a general sense. So complications do arise as we discussed earlier. I interviewed a cardiologist targeting amyloidosis, and there's a periodontist talking about osteonecrosis of the jaw, which means part of the jaw dies. And so you have to have a special periodontist who knows how to replace a tooth or take a tooth out. Dental health is so important. So, that's the second part of the book. And I learned so much going out with these medical professionals who treat the complications."

#IMBCR #MultipleMyeloma #MGUS #Waldenstroms #Amyloidosis #Hematology #Oncology #BerensonCancerCenter #sBCMA #ClinicalResearch #PatientCare #LiveBetterLiveLonger

IMBCR.org

Listen to the podcast here

Debra Berenson is Chair of the Fundraising Committee at the Institute for Myeloma & Bone Cancer Research and author of two books- I Have WHAT and You Have WHAT, based on her personal experience and the expertise of her husband, Dr. Jim Berenson, a myeloma expert. Multiple myeloma and related bone cancers are increasingly common, and her books are designed to help patients and caregivers understand the diagnosis and treatment options. Debra emphasizes that treatments have advanced significantly, leading to much longer, higher-quality lives for patients and transforming these diseases into chronic, manageable conditions.

Debra explains, "I thought, "If I had this disease, what would I do?" And I used to be a reporter, so that's how I told my husband I wanted to write these books - like interviews. I wanted to interview different patients with these diseases. I wanted to get the real stories out there of what it was really like having one of these diseases - the good, bad, and the ugly of dealing with all of them, and what helped these patients and what didn't help them."

"I also thought it would be cathartic for the patient who could share their journey, and also helpful for the new patient. That's the first part of the book - interviews with the different patients who have the four different diseases that Jim treats. The second part of the book is made up of the medical professionals who treat these diseases. I interviewed Jim about myeloma and its related diseases and asked him to weigh in with his medical opinions in a general sense. So complications do arise as we discussed earlier. I interviewed a cardiologist targeting amyloidosis, and there's a periodontist talking about osteonecrosis of the jaw, which means part of the jaw dies. And so you have to have a special periodontist who knows how to replace a tooth or take a tooth out. Dental health is so important. So, that's the second part of the book. And I learned so much going out with these medical professionals who treat the complications."

#IMBCR #MultipleMyeloma #MGUS #Waldenstroms #Amyloidosis #Hematology #Oncology #BerensonCancerCenter #sBCMA #ClinicalResearch #PatientCare #LiveBetterLiveLonger

IMBCR.org

Download the transcript here

Anthony Tardi, head of ultrasound and radiology CT at Samsung HME America, is developing non-invasive, portable tools such as quantitative ultrasound to enable earlier detection of diseases that can be reversed if caught early. AI is being used to automate tedious, clerical tasks in imaging, allowing clinicians to focus more on the patient and clinical assessment. Improving gateway imaging, such as ultrasound and X-rays, is seen as a way to benefit the entire healthcare system by potentially reducing the need for more expensive scans.

Anthony explains, "We're developing technologies that use ultrasound to have a non-invasive tool that reduces the ionizing radiation and is able to quickly identify different levels of hepatic steatosis using quantitative ultrasound. So we're developing tools that, instead of getting a patient needing to have a biopsy or maybe another modality that may be more expensive or not accessible, such as MRI, we're able to develop tools using ultrasound to be able to acquire that information. So that would just be one example."

"So technology continues to evolve. I would say in the case of this particular technology, it's a combination of automation being implemented. We have access to some of the best hardware and semiconductor innovation, and we integrate those into the ultrasound systems. That gives us a little more power and automation, enabling us to access new levels of information beyond the traditional norm, I would say, in imaging."

#SamsungHMEAmerica #SamsungHealthcare #MedicalImaging #HealthcareInnovation #ImagingInnovation #PatientCare #MedicalEquipment #UltrasoundInnovation #HealthTech #Ultrasound #Radiology #AIinHealthcare #DigitalHealth

usa.samsunghealthcare.com

Listen to the podcast here

Anthony Tardi, head of ultrasound and radiology CT at Samsung HME America, is developing non-invasive, portable tools such as quantitative ultrasound to enable earlier detection of diseases that can be reversed if caught early. AI is being used to automate tedious, clerical tasks in imaging, allowing clinicians to focus more on the patient and clinical assessment. Improving gateway imaging, such as ultrasound and X-rays, is seen as a way to benefit the entire healthcare system by potentially reducing the need for more expensive scans.

Anthony explains, "We're developing technologies that use ultrasound to have a non-invasive tool that reduces the ionizing radiation and is able to quickly identify different levels of hepatic steatosis using quantitative ultrasound. So we're developing tools that, instead of getting a patient needing to have a biopsy or maybe another modality that may be more expensive or not accessible, such as MRI, we're able to develop tools using ultrasound to be able to acquire that information. So that would just be one example."

"So technology continues to evolve. I would say in the case of this particular technology, it's a combination of automation being implemented. We have access to some of the best hardware and semiconductor innovation, and we integrate those into the ultrasound systems. That gives us a little more power and automation, enabling us to access new levels of information beyond the traditional norm, I would say, in imaging."

#SamsungHMEAmerica #SamsungHealthcare #MedicalImaging #HealthcareInnovation #ImagingInnovation #PatientCare #MedicalEquipment #UltrasoundInnovation #HealthTech #Ultrasound #Radiology #AIinHealthcare #DigitalHealth

usa.samsunghealthcare.com

Download the transcript here

Dr. Heather Bassett, Chief Medical Officer at Xsolis, is using AI to reduce friction between healthcare providers and payers in the utilization management and mid-revenue cycle space. Their Care Level Score is a data-driven metric derived from patient data to reduce manual processes, denials, and administrative costs for both hospitals and insurance companies. The system enables automated approvals for clear-cut cases, reduces repetitive administrative work, and reduces delays in patient diagnoses and treatment initiation.

Heather explains, "We're an AI company at heart. We work with acute care hospitals across the US. We live in what's called the utilization management and mid-revenue cycle space, which, to put that in layman's terms, is we make sure that hospitals get paid appropriately for the care they provide their patients."

"We recognized fairly quickly that there was just a tremendous amount of complexity in manual processes and saw an opportunity to layer in automation and AI to help decrease a lot of the friction, get rid of the manual processes. And then a larger opportunity we saw was to ease much of the friction between hospitals and providers and payers. And that's really where we've helped our clients solve that problem and move the needle forward."

"Unfortunately, there is an increase in the number of denials, and that requires a lot of rework and submission on the hospital side. And also, when you look at what's happening, when the hospital is submitting information to get authorization for that inpatient hospital-level of care, they're doing a manual review and sending information to the payer. Well, there's a UR, utilization review, nurse on the payer side who is doing exactly the same thing, and a good percentage of the time they're coming to the same conclusion."

#Xsolis #HealthcareAI #UtilizationManagement #RevenueCycle #PriorAuth #PayerProvider #ClinicalAI #HealthIT

xsolis.com

Listen to the podcast here

Dr. Heather Bassett, Chief Medical Officer at Xsolis, is using AI to reduce friction between healthcare providers and payers in the utilization management and mid-revenue cycle space. Their Care Level Score is a data-driven metric derived from patient data to reduce manual processes, denials, and administrative costs for both hospitals and insurance companies. The system enables automated approvals for clear-cut cases, reduces repetitive administrative work, and reduces delays in patient diagnoses and treatment initiation.

Heather explains, "We're an AI company at heart. We work with acute care hospitals across the US. We live in what's called the utilization management and mid-revenue cycle space, which, to put that in layman's terms, is we make sure that hospitals get paid appropriately for the care they provide their patients."

"We recognized fairly quickly that there was just a tremendous amount of complexity in manual processes and saw an opportunity to layer in automation and AI to help decrease a lot of the friction, get rid of the manual processes. And then a larger opportunity we saw was to ease much of the friction between hospitals and providers and payers. And that's really where we've helped our clients solve that problem and move the needle forward."

"Unfortunately, there is an increase in the number of denials, and that requires a lot of rework and submission on the hospital side. And also, when you look at what's happening, when the hospital is submitting information to get authorization for that inpatient hospital-level of care, they're doing a manual review and sending information to the payer. Well, there's a UR, utilization review, nurse on the payer side who is doing exactly the same thing, and a good percentage of the time they're coming to the same conclusion."

#Xsolis #HealthcareAI #UtilizationManagement #RevenueCycle #PriorAuth #PayerProvider #ClinicalAI #HealthIT

xsolis.com

Download the transcript here